March 22 at 2:54 pm
Connect Biopharma: Phase 2b Data Shows Rapid and Sustained Improvement in Atopic Dermatitis
Global clinical-stage biopharmaceutical company, Connect Biopharma (Nasdaq: CNTB), has announced that post hocdata analysis from its Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis… [Read More]